Prexasertib in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors
Conditions
- Childhood Solid Neoplasm
- Recurrent Malignant Solid Neoplasm
- Recurrent Primary Central Nervous System Neoplasm
- Refractory Malignant Solid Neoplasm
- Refractory Primary Central Nervous System Neoplasm
Interventions
- OTHER: Laboratory Biomarker Analysis
- OTHER: Pharmacokinetic (PK) study
- DRUG: Prexasertib
Sponsor
Children's Oncology Group
Collaborators